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(Shelhigh, Inc, Milburn, NJ).
Methods: From November 1998 through December 2007, 175 patients with a mean age of 71.1  7.4 years un-
derwent aortic root replacement with a Shelhigh biological conduit. Indication for surgery was aneurysmal dis-
ease of the aorta in 120 (68.6%) patients, aortic valve endocarditis in 20 (11.4%), acute type A aortic dissection in
11 (6.3%), and other in 24 (13.7%) patients.
Results: Overall hospital mortality was 13.7% (n ¼ 24; 95% confidence limits, 9.0%–19.7%). Cause of death
was cardiac failure in 12 patients, central neurologic damage in 5 patients, pulmonary in 3 patients, gastrointes-
tinal ischemia in 2 patients, and aorta-related in 2 patients. Mean follow-up was 3.1 years (range 0.2–9.9 years). In
total, 50 (33.1%) late deaths occurred; of these 7 were valve-related. The overall survival at 1 and 5 years is
77.6% 3.2% and 54.6% 4.6% respectively. Six (4.0%) patients required reoperation, either for endocarditis
of the bioconduit (n¼ 5) or for false aneurysm (n¼ 1). Endocarditis of the bioconduit was reported in 11 (7.3%)
patients, of whom 6 were treated nonoperatively and 5 required reoperation.
Conclusions: Midterm results of the implantation of the Shelhigh biological valved conduit are worrisome.
The relatively high incidence of endocarditis of the Shelhigh BioConduit has forced us to look for other alterna-
tives. (J Thorac Cardiovasc Surg 2011;141:1157-62)Bentall and DeBono1 described the first complete replace-
ment of the aortic rootwith a conduit in 1968. The initial com-
posite valved graft contained a mechanical valve, but
nowadays there are also complete biological conduits as sub-
stitutes for aortic root replacement. The homograft or auto-
graft is an alternative but has the disadvantage of limited
donor availability and durability.2 Aortic valve–sparing
surgery may not be applicable for all pathologic situations
of the aortic root and in particular the aortic valve.3,4
Nowadays, only a few biological valved conduits are
readily available off the shelf in all sizes and without
the need for lifelong oral anticoagulation. At the end of the
1990s, a new stentless biological valved conduit, the
Shelhigh BioConduit model NR-2000C (Shelhigh, Inc,
Milburn, NJ), was introduced. This is a bovine pericardial
straight graft with an incorporated porcine stentless valve,
which is glutaraldehyde cross-linked, detoxified, and heparin
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The Journal of Thoracic and Carbiological valved conduit for aortic root replacement in
elderly patients or for specific indication, such as infective
aortic root abscesses. In this report we describe and analyze
our initial results.
PATIENTS AND METHODS
Patients
From November 1998 through December 2007, 175 patients with
a mean age of 71.1 years (range, 31–84 years) underwent aortic root replace-
ment with a Shelhigh BioConduit model NR-2000C. Fifty-two (29.7%) pa-
tients were 75 years or older. There were 102 (58.3%) male and 73 (41.7%)
female patients. The ethics committee approved this retrospective cohort
study and waived the need for patient consent. Aortic root diseases treated
with this complete biological conduit consisted of the following: aneurysm,
n ¼ 120 (68.6%); aortic valve endocarditis, n ¼ 20 (11.4%); acute type A
aortic dissection, n ¼ 11 (6.3%), calcified (‘‘porcelain’’) aortic root, n ¼ 8
(4.6%); and other, for example, small aortic annulus or aortic stenosis ow-
ing to pannus formation after previous aortic valve replacement, n ¼ 16
(9.1%). The intervention was a reoperation after previous cardiac surgery
in 45 patients (25.7%), of whom themajority (33 patients) had previous aor-
tic valve surgery. Twenty-two (12.6%) patients were treated under emer-
gency conditions. Four (2.3%) patients were preoperatively supported
with the ventilator, mainly owing to complicated type A aortic dissection
or prosthetic valve endocarditis. Comorbid medical conditions consisted
of hypertension (n ¼ 123, 70.3%), renal dysfunction (n ¼ 25, 14.3%; se-
rum creatinine> 120 mmol/L, among whom 2 required hemodialysis),
chronic obstructive pulmonary disease (n ¼ 23, 13.1%), previous cerebro-
vascular accident or transient ischemic attack (n ¼ 16, 9.1%), diabetes
(n¼ 13, 7.4%), andMarfan syndrome (n¼ 3, 1.7%). Mean aortic diameter
for aneurysmatic disease was 59.7  10.1 mm (range, 43–108 mm). Con-
comitant aortic valve disease consisted of severe aortic regurgitation
(grade 3) in 88 (50.3%) patients, moderate to severe aortic valve stenosis
(mean gradient, 65.6  25.6 mm Hg) in 54 (30.9%) patients, and mixeddiovascular Surgery c Volume 141, Number 5 1157
TABLE 1. Patient characteristics (n ¼ 175)
No. %
Age (y)
Mean (SD; range) 71.1 (7.4; 31–84)
Gender
Male 102 58.3
NYHA class
I 30 17.1
II 62 35.5
III 53 30.3
IV 30 17.1
Indication
Aneurysmatic disease 120 68.6
Degenerative 110
False 6
Postdissection 4
Aortic valve endocarditis 20 11.4
Prosthetic 16
Native 4
Acute type A dissection 11 6.3
Calcified aortic root 8 4.6
Other 16 9.3
Valvular disease
Aortic valve regurgitation
Grade I 55 31.4
Grade II 32 18.3
Grade III 55 31.4
Grade IV 33 18.9
Aortic valve stenosis 54 30.9
Mean gradient, mm Hg (SD; range) 65.6 (25.6; 20–135)
Mixed aortic valve lesion 26 14.9
Bicuspid aortic valve 16 9.1
Reoperation 45 25.7
Previous aortic valve surgery 33
Comorbid medical conditions
Hypertension 123 70.3
Renal insufficiency 25 14.3
COPD 23 13.1
CVA 21 12.0
Diabetes 13 7.4
Marfan 3 1.7
SD, Standard deviation;NYHA, NewYork Heart Association;COPD, chronic obstruc-
tive pulmonary disease; CVA, cerebral vascular accident.
Abbreviations and Acronyms
CL ¼ confidence limits
OR ¼ odds ratio
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Daortic valve lesion in 26 (14.9%) patients. A bicuspid aortic valve was
present in 16 (9.1%) patients. Preoperative mitral valve regurgitation
(grade  3) as a comorbid cardiac lesion was present in 8 (4.6%) patients
and coronary artery disease in 46 (26.3%) patients. Pertinent patient data
are given in Table 1.
Procedure
Full aortic root replacement for insertion of a composite valved graft with
the button technique for reattachment of the coronary ostia was used in all
patients in combination with standard cardiopulmonary bypass.5 The aortic
cannulation site was mainly the distal ascending aorta or the common fem-
oral artery in case of a reoperation or a type A dissection. Cold crystalloid
cardioplegic solution cardioplegia was administered antegradely through
the aortic root or coronary ostia selectively with intermittent cardioplegic re-
infusion if needed. During cardioplegic arrest, the myocardial septal temper-
ature was measured and kept around 10C using a Shumway cold line.
Depending on the aortic disease, the location and extension of the lesion,
a distal clamp could be used in 67 (38.3%) patients. If the lesion extended
to the aortic arch necessitating open distal anastomosis, deep hypothermic
circulatory arrest was used in 63 (36.0%) patients and antegrade selective
cerebral perfusion with mild hypothermia was used in 45 (25.7%). The lat-
ter technique was used when a circulatory arrest period of more than 30min-
utes was anticipated.6,7 The proximal suture technique was by preference of
the surgeon and consisted of 3 separate, continuous 4–0 polypropylene
sutures (n ¼ 108, 61.7%) for the attachment of the BioConduit sewing
ring to the aortic annulus or interrupted pledget-supporteded 2–0 braided
polyester mattress sutures (n ¼ 67, 38.3%). In recent years a continuous
5–0 polypropylene suture was used to reinforce the proximal annular anas-
tomosis against anastomotic leakage.
The diameter of the implanted biological conduits ranged from 21 to 27
mm with a median of 25 mm. Aortic root replacement solely was done in
only 12 (6.9%) patients. Aortic root and distal ascending aorta replacement
was realized in 72 (41.1%) patients. Root replacement and ascending aorta
with partial arch replacement was effected in 68 (38.9%) patients. Finally,
aortic root, ascending aorta, and total arch replacement with or without el-
ephant trunk was performed in 23 (13.1%) patients. In 99 (56.6%) patients,
a woven vascular graft was used as an extension of the BioConduit and the
native downstream aorta. The graft diameter ranged from 22 to 32 mm with
a median of 26 mm.
Concomitant procedures included planned coronary artery bypass graft-
ing in 41 (23.4%) patients, coronary artery bypass grafting owing to pero-
perative technical problems in 6 (3.4%) patients, mitral valve repair or
replacement in 5 (2.9%) patients, combination of planned coronary artery
bypass grafting and mitral or tricuspid valve surgery in 5 (2.9%) patients,
or other procedures, such as theMorrowprocedure or closure of an atrial sep-
tal defect, in 7 (4.0%) patients. Operative data are given in detail in Table 2.
Follow-up
Recent (<6 months) information about the status of all hospital survivors
was collected from the referring cardiologist, by visit at our outpatient clinic,
by our cardiology department, or by the general physician. December 31,
2008, was the closing date for follow-up and included physical examination,
computed tomography scan, echocardiography, and chest radiography, if
available. End points of the studywere death, valve-related death, reoperation
for valve failure, and endocarditis of the BioConduit. These end points were
defined according to the guidelines reported by Akins and associates.81158 The Journal of Thoracic and Cardiovascular SurData Analysis
Retrospective review was done on the data of all consecutive patients
who underwent aortic root replacement with the Shelhigh BioConduit.
Quantitative data are presented as mean  standard deviation. Odds ratios
(OR) and Fisher’s exact P value were used for comparison. Kaplan–Meier
survival curves were used for analysis of survival times. Precision was in-
dicated by 95% confidence limits (CL). All statistical analyses were done
by R (version 2.9; www.r-project.org).RESULTS
Early Results
Overall hospital mortality was 13.7% (n ¼ 24; 95% CL,
9.0%–19.7%), of which 8.5% was for elective and 50.0%gery c May 2011
TABLE 2. Operative characteristics (n ¼ 175)
No. %
Emergency
Elective 153 87.4
Emergency 22 12.6
Cannulation site
Ascending aorta 134 76.6
Common femoral artery 39 22.3
Axillary artery 2 1.1
Perfusion data
CPB and distal clamp 67 38.3
DHCA 63 36.0
ASCP 45 25.7
CPB time; min, mean (SD; range) 190.4 (53.6; 117 - 376)
Aortic crossclamp time 125.1 (30.2; 73 - 228)
DHCA time 24.5 (5.9; 17 - 40)
ASCP time 57.1 (14.8; 38 - 79)
Conduit suture technique
Continuous polypropylene sutures 108 61.7
Interrupted pledget-supporteded
polyester sutures
67 38.3
Extent of aorta replacement
Root only 12 6.9
þAscending 72 41.1
þAscending and partial arch 68 38.9
þAscending and total arch 6 3.4
þAscending, total arch and ET 17 9.7
Concomitant procedure
CABG planned 41 23.4
CABG unplanned 6 3.4
Mitral valve repair or replacement 5 2.9
Combination 5 2.9
Other 7 4.0
CPB, Cardiopulmonary bypass; DHCA, deep hypothermic circulatory arrest; ASCP,
antegrade selective cerebral perfusion; SD, standard deviation; ET, elephant trunk;
CABG, coronary artery bypass grafting.
TABLE 3. Causes of early and late death (n ¼ 74)
Causes of death No. %
Early: In hospital 24 13.7
Operative 3 1.7
Elective: arrhythmia 1
Emergency
Heart failure 1
Ischemic 1
Postoperative, hospital 21 12.0
Elective 14
Cardiac 6
Cerebrovascular accident 3
Respiratory failure 3
Bleeding (proximal anastomosis) 2
Emergency 7
Cardiac 2
Cerebrovascular accident 2
Respiratory failure 1
Gastrointestinal ischemia 2
Late: Follow-up 50 33.1
Prosthesis related 7 4.6
Endocarditis* 7
Early (<1 y) 4
Late (>1 y) 3
Cardiac 8 5.3
Ischemic 4
Heart failure 2
Arrhythmia 1
Endocarditis MV prosthesis 1
Neurologic 7 4.6
Cerebrovascular accident 6
Meningitis 1
Respiratory failure 3 2.0
Cancer 7 4.6
(Peripheral) vascular 4 2.7
Dissection 2
Ruptured aneurysm 2
Sudden, unexplained 14 9.3
MV, Mitral valve.
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emergency surgery who died had acute type A dissection or
endocarditis, and the predominant causes of death were
ischemic cardiac or severe neurologic causes. There were 3
(1.7%) intraoperative deaths. All patients who died intrao-
peratively had poor left ventricular function (ejection
fraction 25%), 2 had emergency operations, and the causes
of death were cardiac failure, myocardial infarction, and
electromechanical dissociation after ventricular fibrillation.
Causes of in-hospital death are summarized in Table 3.
Univariate analysis showed acute type A dissection (OR,
9.7; 95% CL, 2.7–35.2; P ¼ .0005), endocarditis (OR, 4.4;
95% CL, 2.5–7.7; P ¼ .0058), and emergency operation
(OR, 10.8; 95% CL, 6.4–18.1; P< .0001) as important
variables for hospital mortality. Multivariate analysis did
not produce any independent predictor. Especially, there
was no independent association between indication type
and emergency operation on hospital mortality. The hospital
mortality for patients with an aortic aneurysm (nondissectionThe Journal of Thoracic and Carand nonendocarditis) having elective surgery was 4.2%
(n ¼ 5). In 6 (3.4%) patients, an intraoperative problems re-
quired a second cardiopulmonary bypass run and in 5 of these
patients a second crossclamp of the aorta with cardioplegic
arrest was necessary. Main cause was to obtain control of
bleeding from the proximal suture line or left coronary ostial
anastomosis.
Mean and median intensive care unit stay was 6 days and
3 days, respectively (range, 1–60 days). Thirty-one (18.0%)
patients needed ventilatory support for more than 48 hours
and a tracheostomy was inserted in 9 (5.2%) patients. A re-
thoracotomy was performed in 48 (27.9%) patients, mostly
for excessive bleeding (n ¼ 18), because of diffuse leakage
(n ¼ 8) from the coronary reattachment line (n ¼ 4), distal
BioConduit suture line (n¼ 2), proximal BioConduit suture
line (n ¼ 2), or other (n ¼ 2). Signs of tamponade (n ¼ 17)diovascular Surgery c Volume 141, Number 5 1159
FIGURE 1. Survival curve after aortic root replacement with a Shelhigh
BioConduit for the elective, emergency, and total group.
FIGURE 2. Freedom from reoperation after aortic root replacement with
a Shelhigh BioConduit.
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half of these patients (n¼ 9) did have a clear tamponade dur-
ing the rethoracotomy. A planned rethoracotomy in the next
few days for removal of gauzes (n¼ 12) was the third major
cause of rethoracotomy. Perioperative myocardial damage
(serum creatinine kinase level>300 IU/L, with a creatinine
kinaseMB isoenzyme fraction>5%) occurred in 14 (8.1%)
patients. Permanent pacemaker implantation was necessary
in 17 (9.9%) patients. Postoperative temporary hemodialy-
sis was necessary in 7 (4.1%) patients. Three of these pa-
tients died in the hospital, the others recovered without the
need for long-term dialysis.
New neurologic symptoms were observed in 23 (13.1%)
patients. Ischemic cerebral accidents occurred in 19 patients,
critical illness polyneuropathy in 2 patients, and transient
peripheral neuropathy in 2 patients. In the stroke group, 7 pa-
tients died in the hospital, 2 of nonneurologic causes, and
permanent neurologic damage was manifest in 6 (3.4%)
patients. The OR for ischemic stroke in the group having
deep hypothermic circulatory arrest was 4.6 (95% CL,
1.7–12.8; P ¼ .0035) in comparison with the group having
antegrade selective cerebral perfusion and distal clamping.
Late Results
There were 151 hospital survivors and all were entered in
the follow-up study (100% complete). Mean and median
follow-up were 3.1 years and 2.9 years, respectively (range
0.2–9.9 years). Total follow-up was 543 patient-years. Dur-
ing follow-up, 50 (33.1%) patients died, and 15 of these
deaths occurred in the first postoperative year. Causes of
death during follow-up are summarized in Table 3. Seven
of these late deaths were prosthesis related owing to endo-
carditis of the BioConduit. Among the other 43 patients
with non–prosthesis-related late deaths, 8 patients died of
cardiac causes, 1 of whom had recurrent endocarditis of
the mitral valve prosthesis (Shelhigh), with vegetations on
echocardiography. The overall survivals at 1 and 5 years
are 77.6%  3.2% and 54.6%  4.6%, respectively.
This information is presented in Figure 1 for the total group
and selectively for the patients having elective and emer-
gency operations. For the complete follow-up period, there
is a significant difference between the elective and emer-
gency groups (P¼ .003). After exclusion of the first 30 post-
operative days, this difference disappears (P ¼ .679).
Six (4.0%) patients required reoperation for significant
prosthesis dysfunction owing to endocarditis of the BioCon-
duit (n¼ 5) and false aneurysm (n¼ 1). Mean length of time
between the initial aortic root replacement and reoperation
was 21.7 months  22.1 months. Three patients underwent
reoperation within 1 year after the initial root replacement,
and in all these cases the cause of reoperation was endocar-
ditis. During reoperation most patients received a second
Shelhigh BioConduit, except 1 patient who received a homo-
graft. One patient, known to have a false aneurysm, is being1160 The Journal of Thoracic and Cardiovascular Surfollowed up conservatively because she underwent multiple
sternal wound explorations, and a reoperation for false aneu-
rysm correction is estimated to be too high a risk. One patient
died after reoperation for endocarditis. One- and 5-year free-
dom from reoperation is 76.4% 3.2% and 50.8 4.6% as
presented in Figure 2.
Endocarditis of the Shelhigh BioConduit was reported in
11 (7.3%) patients. Five of these patients were reoperated on
and only 1 patient died 3 months after the reoperation, as de-
scribed earlier. Six patients were not referred for surgery by
their cardiologist and were treated medically, and all these
patients died subsequently. Two of them had autopsy, whichgery c May 2011
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for the initial aortic root replacement was prosthetic valve
endocarditis for 1 patient, and the rest of the patients had
new-onset endocarditis of the BioConduit with Staphylococ-
cus and Enterococcus as predominant microorganism. The
incidence of late endocarditis was lower in the rethoracot-
omy group (2.1%) than in the nonrethoracotomy group
(7.9%; P ¼ 0.2297). Nine (81.8%) of the 11 patients who
had new-onset endocarditis received the implant after the
year 2003. Mean interval between initial aortic root replace-
ment and new-onset endocarditis was 18.9 months  20.4
months, with a median of 9.3 months.
Follow-up imaging was mostly done by computed tomog-
raphy scan. This was available for 82 (81.2%) patients and
showed the 2 cases of false aneurysm as described earlier.
Distal native aorta diameter increased in 5 patients without
indication for reoperation. Dilatation or calcification of the
pericardial tube was not observed. Echocardiographic eval-
uation of the BioConduit function was performed by most
referring cardiologists when there was a clinical indication.
A recent echocardiographic assessment of the BioConduit
function was available in 43 (42.6%) survivors. Apart
from adequate valve function, this showed previously men-
tioned vegetations and false aneurysms. Besides, there were
2 patients with moderate aortic regurgitation and 3 patients
with moderate aortic stenosis (mean gradient, 50.7  12.9
mm Hg) during a mean follow-up of 3.1 years.
DISCUSSION
The aortic homograft was the first complete biological
composite valved graft used in our center, predominantly
for endocarditis and for relatively young patients. Its limited
donor availability and suboptimal long-term durability has
made us less enthusiastic to use this graft.2 As an alternative,
commercially available stentless biological valved conduits
were introduced, which have the benefit of being readily
available off the shelf in all sizes. The Shelhigh BioConduit
is such a biological composite valved graft. We used this Bi-
oConduit predominantly in elderly patients (mean age, 71
years) with degenerative aortic root disease, but also in pa-
tients with aortic valve endocarditis (mean age, 64 years) be-
cause of its complete biological aspect.
The limited initial results with the Shelhigh BioConduit in
the literaturewere promising,with good clinical and echocar-
diographic results, even in patients with active infective
endocarditis.9-11 Recently, the US Food and Drug
Administration published a preliminary public health
notification on possible contamination and malfunction of
devices manufactured by Shelhigh, Inc.12 After this, Carrel
and associates13,14 reported several precarious cases of
reoperations and unexplained deaths occurring after
implantation of the Shelhigh BioConduit. In their total
group of 115 patients who received a Shelhigh BioConduit,
7 (6.1%) had ‘‘sudden disastrous findings’’ and 4 of themThe Journal of Thoracic and Carrequired emergency reoperation. In our series, 11 (7.3%)
patients had blood culture–positive endocarditis and 5
of them required reoperation. Patients with endocarditis of
the BioConduit who were not referred for surgery all died,
and in 2 of these patients endocarditis was proven by
autopsy. Our aggressive rethoracotomy policy did not
have a significant effect on late endocarditis because
the incidence of late endocarditis was lower in the
rethoracotomy group than in the nonrethoracotomy group
(2.1% vs 7.9%; P ¼ .2297).
Beside endocarditis of the BioConduit, there were 2 in-
stances of false aneurysm formation at the BioConduit and
the number of patients with sudden, unexplained death
was relatively high (9.3%). Unfortunately, we could not
find detailed information about the cause of death of these
patients (mean age, 75.8  8.4 years). It is conceivable
that there might be some sudden, unexplained deaths be-
cause of endocarditis of the BioConduit. If we look at the
7.3% incidence of endocarditis of the Shelhigh BioConduit
in this study and in our previous homograft series, we note
that the incidence of endocarditis of the homograft was
only 3.2%, despite a higher number of patients with endo-
carditis as the initial indication for surgery.2 A true compar-
ison, however, is not valid, because the patient groups are
not comparable. It is important to note that most of the endo-
carditis of the BioConduit cases (81.8%) were Shelhigh
conduits implanted after 2003. In 2007 the Food and Drug
Administration published its preliminary public health noti-
fication. As a consequence, we have now strictly limited the
implantation of the Shelhigh BioConduit for extensive aortic
valve endocarditis complicated by annular abscesses. In the
elective setting, we are in search of an alternative for the
Shelhigh BioConduit.
Because of the lack of published clinical experience reports
specifically about the Shelhigh BioConduit, we sought litera-
ture concerning other stentless biological conduits.15-19
Compared with these reports, our operative mortality of
1.7% and hospital mortality of 13.7% satisfies in a group
with a mean age of 71 years, extended graft repair of the
ascending aorta (41%), and involved aortic arch repair
(52%) with aortic valve endocarditis (11.4%) or acute type
A dissection (6.3%) in 17.7% of the patients. The
incidence of endocarditis of the stentless biological conduits
in these reports is lower than our 7.3%. The freedom from
reoperation is comparable with these reports.
In conclusion, although perioperative results are satisfac-
tory, the follow-up results are worrisome and the relatively
high incidence of endocarditis of the Shelhigh BioConduit
in our retrospective single-center analysis has led us to
change our policy. There is a need for other centers to report
their experiences as well, to draw more solid conclusions.
Patients who have received the Shelhigh BioConduit
should be monitored closely and long-term results should
be evaluated.diovascular Surgery c Volume 141, Number 5 1161
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